{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:38:08Z","timestamp":1792726688288,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016479","name":"Jazz Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.eplepsyres.2026.107873","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:59:04Z","timestamp":1784044744000},"page":"107873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Nonseizure outcomes"],"prefix":"10.1016","volume":"227","author":[{"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Moore-Ramdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Navetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4293","authenticated-orcid":false,"given":"Antonietta","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2026.107873_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108538","article-title":"Effects of Epidiolex\u00ae (cannabidiol) on seizure-related emergency department visits and hospital admissions: A retrospective cohort study","volume":"127","author":"Abu-Sawwa","year":"2022","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib2","unstructured":"Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica, 2023. ANMAT Disposici\u00f3n N\u00ba 3782-23, Convupidiol. Accessed 22 September 2025. https:\/\/boletin.anmat.gob.ar\/mayo_2023\/Dispo_3782-23.pdf."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib4","first-page":"1","article-title":"The Cannabinoids International Experts Panel; Collaborators","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epilepsy and cannabidiol: A guide to treatment"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.seizure.2021.11.020","article-title":"High dose cannabidiol (CBD) in the treatment of new-onset refractory status epilepticus (NORSE)","volume":"94","author":"Aydemir","year":"2022","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107873_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/neurolint13040055","article-title":"Inherited developmental and epileptic encephalopathies","volume":"13","author":"Bartolini","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107280","article-title":"Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey","volume":"200","author":"Berg","year":"2024","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107287","article-title":"Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennox-Gastaut syndrome, ESES: A functional framework","volume":"111","author":"Berg","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.20517\/rdodj.2025.29","article-title":"Evidence evaluation in rare disease guidelines: A methodological perspective","volume":"4","author":"Bolz-Johnson","year":"2025","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109245","article-title":"Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures","volume":"143","author":"Caraballo","year":"2023","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.eplepsyres.2026.107873_bib11","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1111\/epi.18378","article-title":"Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real-world study","volume":"66","author":"Cerulli Irelli","year":"2025","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107873_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5694\/mja18.00023","article-title":"Cannabidiol for treating drug-resistant epilepsy in children: The New South Wales experience","volume":"209","author":"Chen","year":"2018","journal-title":"Med. J. Aust."},{"issue":"8","key":"10.1016\/j.eplepsyres.2026.107873_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/dmcn.15187","article-title":"Caregiver assessment of quality of life in individuals with genetic developmental and epileptic encephalopathies","volume":"64","author":"Cohen","year":"2022","journal-title":"Dev. Med. Child. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2026.107731","article-title":"A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events","volume":"220","author":"Coppola","year":"2026","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/epi4.12796","article-title":"Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome","volume":"9","author":"Desnous","year":"2024","journal-title":"Epilepsia Open."},{"issue":"21","key":"10.1016\/j.eplepsyres.2026.107873_bib16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.eplepsyres.2026.107873_bib17","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107873_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.seizure.2022.11.006","article-title":"Cannabidiol in refractory status epilepticus: A review of clinical experiences","volume":"103","author":"Duda","year":"2022","journal-title":"Seizure. Eur. J. Epilepsy"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2023.09.015","article-title":"Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex","volume":"112","author":"Espinosa-Jovel","year":"2023","journal-title":"Seizure. Eur. J. Epilepsy"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib22","unstructured":"European Medicines Agency, 2025. Epidyolex. Accessed 22 September 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107873_bib23","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.jval.2023.03.593","article-title":"EE292 health care resource utilization and medical costs before and after initiation of Epidiolex in commercially insured patients in the US","volume":"26","author":"Fang","year":"2023","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.eplepsyres.2026.107873_bib24","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.3390\/ijerph18083993","article-title":"Efficacy of phytocannabinoids in epilepsy treatment: Novel approaches and recent advances","volume":"18","author":"Farrelly","year":"2021","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109409","article-title":"Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center","volume":"147","author":"Ferrera","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib26","article-title":"A case of clinical worsening after stereo-electroencephalographic-guided radiofrequency thermocoagulation in a patient with polymicrogyria","volume":"21","author":"Ferri","year":"2023","journal-title":"Epilepsy Behav. Rep."},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107873_bib27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/epi4.12740","article-title":"Cannabidiol in the acute phase of febrile infection-related epilepsy syndrome (FIRES)","volume":"8","author":"Fetta","year":"2023","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108324","article-title":"Impact of developmental and epileptic encephalopathies on caregivers: A literature review","volume":"124","author":"Gallop","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2019.03.035","article-title":"Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy","volume":"95","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109159","article-title":"Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy","volume":"141","author":"Georgieva","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1335441","article-title":"Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples","volume":"15","author":"Gidal","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J. Child. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib33","first-page":"232","article-title":"Resolution of seizures and normalization of EEG after initiation of CBD in a patient with Doose syndrome","volume":"15","author":"Gold","year":"2015","journal-title":"Epilepsy Curr."},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1152\/physrev.00063.2021","article-title":"Developmental and epileptic encephalopathies: From genetic heterogeneity to phenotypic continuum","volume":"103","author":"Guerrini","year":"2023","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107873_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.neurol.2024.03.004","article-title":"Epileptic encephalopathies and progressive neurodegeneration","volume":"180","author":"Guerrini","year":"2024","journal-title":"Rev. Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107873_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3129\/i08-001","article-title":"Age-related macular degeneration and low-vision rehabilitation: A systematic review","volume":"43","author":"Hooper","year":"2008","journal-title":"Can. J. Ophthalmol."},{"issue":"01","key":"10.1016\/j.eplepsyres.2026.107873_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0043-57008","article-title":"Efficacy of cannabidiol in pediatric patients: Postmarket experience at a single center","volume":"22","author":"Hovey","year":"2024","journal-title":"J. Ped. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109412","article-title":"Therapy outcomes associated with prescription cannabidiol use at 12 months post-initiation","volume":"147","author":"Johnson","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.02.009","article-title":"Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome","volume":"71","author":"Kaplan","year":"2017","journal-title":"Ped. Neurol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2026.107873_bib40","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/epi.17332","article-title":"Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress","volume":"63","author":"Knowles","year":"2022","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107873_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/epi4.12411","article-title":"Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy","volume":"5","author":"Kuchenbuch","year":"2020","journal-title":"Epilepsia Open."},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107873_bib42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/epi4.12699","article-title":"Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study","volume":"8","author":"K\u00fchne","year":"2023","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.seizure.2025.12.009","article-title":"An updated overview on clinical and developmental trajectories of developmental and epileptic encephalopathies: From childhood to adulthood","volume":"134","author":"Mastrangelo","year":"2026","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib44","first-page":"370","article-title":"Impact of cannabidiol on quality of life in pediatric drug resistant epilepsy","volume":"15","author":"Morgan","year":"2014","journal-title":"Epilepsy Curr."},{"issue":"23","key":"10.1016\/j.eplepsyres.2026.107873_bib45","first-page":"S70","article-title":"Cannabidiol as a novel treatment for Lafora body disease\u2013A case report","volume":"86","author":"Nayak","year":"2019","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107873_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","article-title":"Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group","volume":"21","author":"Nestler-Parr","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.659543","article-title":"Epileptic phenotype and cannabidiol efficacy in a Williams\u2013Beuren syndrome patient with atypical deletion: A case report","volume":"12","author":"Nicotera","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib48","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.eplepsyres.2026.107873_bib49","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/epi.16936","article-title":"The long-term efficacy of cannabidiol in the treatment of refractory epilepsy","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2024.02.004","article-title":"Real life retrospective study of cannabidiol therapy in alternating hemiplegia of childhood","volume":"49","author":"Patel","year":"2024","journal-title":"Eur. J. Paed. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpn.2019.12.024","article-title":"Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study","volume":"25","author":"Poisson","year":"2020","journal-title":"Eur. J. Paed. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejpn.2022.01.008","article-title":"Is cannabidiol worth a trial in Rasmussen encephalitis?","volume":"37","author":"Prager","year":"2022","journal-title":"Eur. J. Paed. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.586110","article-title":"Cannabidiol treatment for refractory epilepsies in pediatrics","volume":"11","author":"Raucci","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114237","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","volume":"359","author":"Reddy","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2024.01.010","article-title":"Purified cannabidiol as add-on therapy in children with treatment-resistant infantile epileptic spasms syndrome","volume":"115","author":"Reyes Valenzuela","year":"2024","journal-title":"Seizure Eur. J. Epilepsy"},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107873_bib56","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/epi.17240","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: Position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Riney","year":"2022","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107873_bib57","doi-asserted-by":"crossref","DOI":"10.1089\/can.2022.0255","article-title":"Cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy","volume":"9","author":"Riva","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"issue":"8","key":"10.1016\/j.eplepsyres.2026.107873_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/epi.13815","article-title":"Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107873_bib59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.pediatrneurol.2015.02.008","article-title":"Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: A case report","volume":"52","author":"Saade","year":"2015","journal-title":"Ped. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2022.10.014","article-title":"Cannabidiol treatment for neurological, cognitive, and psychiatric symptoms in Sturge-Weber syndrome","volume":"139","author":"Smegal","year":"2023","journal-title":"Ped. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107873_bib61","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2026.107873_bib62","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13311-020-00835-4","article-title":"From genetic testing to precision medicine in epilepsy","volume":"17","author":"Striano","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.eplepsyres.2026.107873_bib63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13643-025-02955-4","article-title":"Integrating case reports into systematic reviews: Methodological strategies and challenges","volume":"14","author":"Taha","year":"2025","journal-title":"Syst. Rev."},{"issue":"4","key":"10.1016\/j.eplepsyres.2026.107873_bib64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.26815\/acn.2022.00269","article-title":"Clinical spectrum and treatment outcomes of patients with developmental and\/or epileptic encephalopathy with spike-and-wave activation in sleep","volume":"30","author":"Tchah","year":"2022","journal-title":"Ann. Child. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2026.107873_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107299","article-title":"Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy","volume":"111","author":"Thompson","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107873_bib67","unstructured":"US Food and Drug Administration,\u00a02025. Epidiolex\u00ae Prescribing Information. Accessed 22 September 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210365s023lbl.pdf."},{"issue":"5","key":"10.1016\/j.eplepsyres.2026.107873_bib68","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/epi4.12956","article-title":"Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex","volume":"9","author":"Wechsler","year":"2024","journal-title":"Epilepsia Open."},{"issue":"7 supplement 1","key":"10.1016\/j.eplepsyres.2026.107873_bib69","first-page":"1","article-title":"Caregiver-reported nonseizure outcomes with real-world use of cannabidiol in tuberous sclerosis complex: Interim results from the BECOME-TSC survey (P8-1.010)","volume":"102","author":"Wilson","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eplepsyres.2026.107873_bib70","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/epi.17274","article-title":"International consensus on diagnosis and management of Dravet syndrome","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107873_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2023.08.033","article-title":"Quality of life in Angelman syndrome: A caregivers\u2019 survey","volume":"149","author":"Xia","year":"2023","journal-title":"Ped. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2026.107873_bib72","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121126001439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121126001439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:55:44Z","timestamp":1792724144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121126001439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":72,"alternative-id":["S0920121126001439"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107873","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Nonseizure outcomes","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107731","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107873"}}